Patent ID: 6228369
Filing Date: 2001-05-08
Classification: A61K,A61P,C07K,C12N

Abstract:
A composition comprising at least:(a) a first DNA sequence coding for a trans-dominant variant of the TAT protein of the HIV virus, placed under the control of the elements needed for a constitutive expression; and(b) a second DNA sequence coding for a trans-dominant variant of the REV protein of the HIV virus, placed under control of the elements needed for a constitutive expression,wherein said composition inhibits viral replication; wherein said first and second DNA sequences are inserted into one or two vectors; andwherein the trans-dominant of the REV protein has the sequence as shown in SEQ ID NO: 2 which comprises the following modifications:(i) the glutamine residue at position +74 is replaced by a glycine residue and the leucine residue at position +75 is replaced by a serine residue; and/or(ii) the glutamine residue at position +74 is replaced by a glycine residue, the leucine residue at position +75 is replaced by a serine residue, the leucine residue at position +78 is replaced by a glutamic acid residue, the glutamic acid residue at position +79 is replaced by a phenylalanine residue and the leucine residue at position +81 is replaced by an aspartic acid residue.